It is suggested that the chronic hyperbilirubinemia leading to a lag-phase prolongation in LDL oxidation and a decrease in LDL oxidation may be reason for the low percentage of coronary artery disease.
The therapeutic efficacy of recombinant interferon-α (rIFN-α) has been evaluated in 7 patients with polycythaemia vera (PV), diagnosed according to the criteria of the Polycythemia Vera Study Group. Six complete responses and one partial response were achieved. Pruritus significantly improved in 80% (4/5) of the cases. Recombinant interferon-α had to be discontinued in 1 patient because of grade 3–4 nephrotoxicity according to WHO criteria. rIFN-α therapy significantly decreased the phlebotomy requirements and improved the mean corpuscular volume, erythrocyte and platelet counts, pruritus complaints and the degree of splenomegaly (p < 0.05). rIFN-α seems to be an effective treatment modality for the myeloproliferation of PV and pruritus complaints.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.